Find drug development pipeline and deal Updates information

Lead Product(s): Metoclopramide

Therapeutic Area: Gastroenterology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Eversana

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement January 23, 2020

Details:

Under the terms of the agreement, Evoke retains Gimoti NDA rights as well as all legal, regulatory and production obligations, while EVERSANA will sell and supply Gimoti in the United States.

Lead Product(s): Metoclopramide

Therapeutic Area: Gastroenterology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 21, 2020

Details:

A six-month period of review from the FDA’s date of receipt has been assigned for the resubmitted NDA and the PDUFA target goal date is June 19, 2020.

Lead Product(s): Etrasimod

Therapeutic Area: Gastroenterology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 06, 2020

Details:

Arena Pharmaceuticals expanded multi-program collaboration with Beacon Discovery for immune and inflammatory targets (Project Cabrillo).